Interdisziplinäre Leitlinien zur Diagnostik und Therapie der extrazerebralen Amyloidosen

Within the past 10 years, a new range of knowledge has been achieved in the field of amyloidosis, especially with regard to pathogenesis, diagnosis and therapy. Amyloidosis leads to variable and distinct symptoms and is caused by different underlying conditions. Some amyloidoses are acquired secondary to a chronic condition; others are caused by genetic mutations. Amyloid and amyloidosis occur more frequently than they are perceived. Among the frequent localized forms are the cerebral amyloidosis linked to Alzheimer disease (AD) and the pancreatic amyloidosis linked to diabetes mellitus. Among the most frequent systemic (extracerebral) forms is AL amyloidosis, which often has a poor prognosis and if untreated can rapidly lead to death. Systemic amyloidosis that happen at infancy are mainly AA amyloidosis that can progress to death already at early or at middle adulthood. Amyloidosis can be treated but therapeutic success significantly depends upon early diagnosis and proper classification of the amyloid type. It is mandatory that differential diagnosis demonstrate the presence of amyloid and clearly identify the type of the disease. Development of methods and techniques have contributed to improvements in the diagnosis and treatment. Early diagnosis and proper classification of amyloid is decisive for therapeutic options and upon them depend quality of life and mortality. The therapeutic spectrum is various and includes organ transplantation, chemotherapy, and anti-inflammatory strategies. Gene therapy and biological active substances have to be considered in the near future.

Schlüsselwörter

Amyloid - Leitlinien - Diagnostik - Therapie

Key words

Amyloid - Guidelines - Diagnostics - Therapy

Literatur

• 1 Adams D, Samuel D, GoulonGoeau C, Nakazato M, Costa P MP, Feray C, Plante V, Ducot B, Ichai P, Lacroix C, Metral S, Bismuth H, Said G. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation.  Brain. 2000;  123 1495-1504
• 2 Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency.  Clin Rheumatol. 1987;  6 27-38
• 3 Ahmed Q, Chung-Park M, Mustafa K, Khan M A. Psoriatic spondyloarthropathy with secondary amyloidosis.  J Rheumatol. 1996;  23 1107-1110
• 4 Alexanian R, Bergsagel D E, Migliore P J, Vaughn W K, Howe C D. Melphalan therapy for plasma cell myeloma.  Blood. 1968;  31 1-10
• 5 Alloni A, Pellegrini C, Ragni T, Goggi C, D’Armini A M, Rinaldi M, Vigano M. Heart transplantation in patients with amyloidosis: single-center experience.  Transplant Proc. 2004;  36 643-644
• 6 Altland K, Winter P, Saraiva M J, Suhr O. Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin.  Neurogenetics. 2004;  5 61-67
• 7 Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation.  Transplantation. 2004;  77 345-349
• 8 Andrade C. A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves.  Brain. 1952;  75 408-427
• 9 Andreola A, Bellotti V, Giorgetti S, Mangione P, Obici L, Stoppini M, Torres J, Monzani E, Merlini G, Sunde M. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I.  J Biol Chem. 2003;  278 2444-2451
• 10 Andrews T R, Colon-Otero G, Calamia K T, Menke D M, Boylan K B, Kyle R A. Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy.  Mayo Clin Proc. 2002;  77 1287-1290
• 11 Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis.  Amyloid. 2002;  9 108-114
• 12 Balakrishnan C, Sule A, Mittal G, Gaitonde S, Pathan E, Rajadhyaksha S, Deshpande R B, Gurmeet M, Samant R, Joshi V R. Treatment of AA amyloidosis in rheumatoid arthritis.  J Assoc Physicians India. 2002;  50 907-909
• 13 Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents.  New Engl J Med. 1984;  310 1353-1356
• 14 Benson M D. Leptomeningeal amyloid and variant transthyretins.  Am J Pathol. 1996;  148 351-354
• 15 Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic diseases.  Ann Rheumatic Diseases. 1987;  46 757-762
• 16 Berk J L, Keane J, Seldin D C, Sanchorawala V, Koyama J, Dember L M, Falk R H. Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis.  Chest. 2003;  124 969-977
• 17 Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. European Group for Blood and Marrow Transplant . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT.  Br J Haematol. 1998;  102 1115-1123
• 18 Blanche P, Menkes C J. Immunosuppressive therapy of secondary amyloidosis associated with rheumatoid arthritis or Still’s disease.  Rev Rhum Mal Osteoartic. 1992;  59 784-789
• 19 Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, Hamidi A K, Benson M D, Donat J R. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His.  Neurology. 2003;  60 1625-1630
• 20 Breedveld F C, Markusse H M, MacFarlane J D. Subcutaneous fat biopsy in the diagnosis of amyloidosis secondary to chronic arthritis.  Clin Exp Rheumatol. 1989;  7 407-410
• 21 Browning M J, Banks R A, Tribe C R, Hollingworth P, Kingswood C, Mackenzie J C, Bacon P A. Ten years’ experience of an amyloid clinic-a clinicopathological survey.  Q J Med. 1985;  54 213-227
• 22 Cameron J S. Nephrotic syndrome in the elderly.  Semin Nephrol. 1996;  16 319-329
• 23 Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide.  Rheumatology (Oxford). 2001;  40 821-825
• 24 Choufani E B, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright D G, Seldin D C. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.  Blood. 2001;  97 1885-1887
• 25 Chugh K S, Datta B N, Singhal P C, Jain S K, Sakhuja V, Dash S C. Pattern of renal amyloidosis in Indian patients.  Postgraduate Med J. 1981;  57 31-35
• 26 Cohen A S, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins.  Nature. 1959;  183 1202-1203
• 27 Comenzo R L, Gertz M A. Autologous stem cell transplantation for primary systemic amyloidosis.  Blood. 2002;  99 4276-4282
• 28 Couverchel L, Maugars Y, Prost A. Outcomes of thirty-four rheumatoid arthritis patients with renal amyloidosis, including twelve given alkylating agents.  Rev Rhum Engl Ed. 1995;  62 79-85
• 29 Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn’s disease.  Am J Gastroenterol. 2001;  96 2107-2112
• 30 David J. Amyloidosis in juvenile chronic arthritis (Review).  Clin Exp Rheumatol. 1991;  9 73-78
• 31 Delgado W A, Aranachavez V E. Amyloid deposits in labial salivary glands identified by electron microscopy.  J Oral Pathol Med. 1997;  26 51-52
• 32 Delgado W A, Mosqueda A. A highly sensitive method for diagnosis of secondary amyloidosis by labial salivary gland biopsy.  J Oral Pathol Med. 1989;  18 310-314
• 33 Dhodapkar M V, Hussein M A, Rasmussen E, Solomon A, Larson R A, Crowley J J, Barlogie B. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.  Blood. 2004;  104 3520-3526
• 34 Dilek K, Usta M, Ersoy A, Ozdemir B, Yavuz M, Gullulu M, Yurtkuran M. Long-term effects of losartan on proteinuria and renal function in patients with renal amyloidosis.  Scand J Urol Nephrol. 2002;  36 443-446
• 35 Dispenzieri A, Gertz M A, Kyle R A, Lacy M Q, Burritt M F, Therneau T M, McConnell J P, Litzow M R, Gastineau D A, Tefferi A, Inwards D J, Micallef I N, Ansell S M, Porrata L F, Elliott M A, Hogan W J, Rajkumar S V, Fonseca R, Greipp P R, Witzig T E, Lust J A, Zeldenrust S R, Snow D S, Hayman S R, McGregor C G, Jaffe A S. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.  Blood. 2004;  104 1881-1887
• 36 Dispenzieri A, Kyle R A, Lacy M Q, Therneau T M, Larson D R, Plevak M F, Rajkumar S V, Fonseca R, Greipp P R, Witzig T E, Lust J A, Zeldenrust S R, Snow D S, Hayman S R, Litzow M R, Gastineau D A, Tefferi A, Inwards D J, Micallef I N, Ansell S M, Porrata L F, Elliott M A, Gertz M A. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.  Blood. 2004;  103 3960-3963
• 37 Dispenzieri A, Lacy M Q, Rajkumar S V, Geyer S M, Witzig T E, Fonseca R, Lust J A, Greipp P R, Kyle R A, Gertz M A. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.  Amyloid. 2003;  10 257-261
• 38 Dode C, Cuisset L, Delpech M, Grateau G. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis.  J Nephrol. 2003;  16 435-437
• 39 Duston M, Skinner M, Shirahama T S, Cohen A S. Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years’ experience.  Am J Med. 1987;  82 412-414
• 40 Elkayam O, Hawkins P N, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.  Arthritis Rheum. 2002;  46 2571-2573
• 41 Ellie E, Camou F, Vital A, Rummens C, Grateau G, Delpech M, Valleix S. Recurrent subarachnoid hemorrhage associated with a new transthyretin variant (Gly53Glu).  Neurology. 2001;  57 135-137
• 42 Ensari C, Ensari A, Tumer N, Ertug E. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients.  Nephrol Dial Transplant. 2005;  20 1721-1725
• 43 Ernst J, Mayer-Schlagintweit S, Wienands K, Albrecht H J. AA-Amyloidose - Therapeutische Beeinflussbarkeit und prognostische Parameter.  Ztschr Rheumatol. 1995;  16 49-52
• 44 Ernst J, Wienands K, Mayer-Schlagintweit S, Bloching H, Saeger W, Albrecht H J. Can specific laboratory constellations improve the indication for rectal biopsy and thus contribute to the early diagnosis of AA amyloidosis in inflammatory rheumatic diseases?.  Clin Neuropathol. 1997;  16 49-52
• 45 Escalante A, Ehresmann G R, Quismorio F P. Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administration of colchicine.  Arthritis Rheum. 1991;  34 920-922
• 46 Fak A S, Ozener C, Akoglu E. Colchicine and secondary amyloidosis.  Ann Intern Med. 1992;  117 795-796
• 47 Falk R H, Comenzo R L, Skinner M. The systemic amyloidoses.  New Engl J Med. 1997;  337 898-909
• 48 Fatihi E, Ramdani B, Fadel H, Hachim K, Zahiri K, Benghanem G M, Sqalli S, Zaid D. Prevalence of subcutaneous, labial, and rectal amyloidosis in patients with renal amyloidosis.  Nephrologie. 2000;  21 19-21
• 49 Fatihi E, Zahiri K, Hachim K, Fadel H, Benghanem G M, Sqalli S, Ramdani B, Zaid D. Diagnostic value of accessory salivary gland biopsy in amyloidosis.  Rev Med Interne. 1999;  20 759-761
• 50 Fiter J, Nolla J M, Valverde J, Roig-Escofet D. Treatment of amyloidosis secondary to rheumatoid arthritis.  J Rheumatol. 1995;  22 569-570
• 51 Frangione B, Vidal R, Rostagno A, Ghiso J. Familial cerebral amyloid angiopathies and dementia.  Alz Dis Assoc Disorder. 2000;  14 S25-S30
• 52 Frederiksen T, Gotzsche H, Harboe N, Kaer W, Mellemgaard K. Familial primary amyloidosis with severe amyloid heart disease.  Am J Med. 1962;  33 328-348
• 53 Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y. A case of multicentric Castleman’s disease associated with renal amyloidosis and pure red cell aplasia.  Amer J Nephrol. 1998;  18 247-250
• 54 Furtado A J. Domino liver transplantation using FAP grafts. HUC experience - hopes and realities.  Amyloid. 2003;  (Suppl 1) 10 84-87
• 55 Gafni J, Sohar E. Rectal biopsy for the diagnosis of amyloidosis.  Amer J Med Sci. 1960;  240 102-332 - 336
• 56 Gardner K D, Castellino R A, Kempson R, Young B W, Stamey T A. Primary amyloidosis in the renal pelvis.  New Engl J Med. 1971;  284 1196-1198
• 57 Genschel J, Haas R, Pröpsting M J, Schmidt H HJ. Apolipoprotein A-I induced amyloidosis.  FEBS Lett. 1998;  430 145-149
• 58 Gertz M A. Diagnosing primary amyloidosis.  Mayo Clin Proc. 2002;  77 1278-1279
• 59 Gertz M A, Comenzo R, Falk R H, Fermand J P, Hazenberg B P, Hawkins P N, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th international symposium on amyloid and amyloidosis.  Am J Haematol . 2005;  79 319-328
• 60 Gertz M A, Kyle R A. Secondary systemic amyloidosis: response and survival in 64 patients.  Medicine (Baltimore). 1991;  70 246-256
• 61 Gertz M A, Kyle R A, O’Fallon W M. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.  Arch Intern Med. 1992;  152 2245-2250
• 62 Gertz M A, Lacy M Q, Dispenzieri A. Immunoglobulin light chain amyloidosis and the kidney.  Kidney Int. 2002;  61 1-9
• 63 Gertz M A, Lacy M Q, Dispenzieri A, Gastineau D A, Chen M G, Ansell S M, Inwards D J, Micallef I N, Tefferi A, Litzow M R. Stem cell transplantation for the management of primary systemic amyloidosis.  Am J Med. 2002;  113 549-555
• 64 Gertz M A, Lacy M Q, Lust J A, Greipp P R, Witzig T E, Kyle R A. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis.  Am J Hematol. 1999;  61 115-119
• 65 Gertz M A, Li C Y, Shirahama T, Kyle R A. Utility of subcutaneous fat aspiration for the diagnosis of systemic amyloidosis (immunoglobulin light chain).  Arch Intern Med. 1988;  148 929-933
• 66 Gertz M A, Noel P, Kyle R A. Second malignancies after chemotherapy and transplantation.  Crit Rev Oncol Hematol. 1993;  14 107-125
• 67 Gillmore J D, Hawkins P N, Pepys M B. Amyloidosis: A review of recent diagnostic and therapeutic developments.  Br J Haematol. 1997;  99 245-256
• 68 Gillmore J D, Lovat L B, Persey M R, Pepys M B, Hawkins P N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.  Lancet. 2001;  358 24-29
• 69 Godbersen G S, Leh J F, Hansmann M L, Rudert H, Linke R P. Organ-limited laryngeal amyloid deposits: clinical, morphological, and immunohistochemical results of five cases.  Ann Otol Rhinol Laryngol. 1992;  101 770-775
• 70 Golling M, Singer R, Weiss G, Mehrabi A, Zapletal C, Kraus T, Herfarth C, Klar E. Sequential (Domino) transplantation of the liver in a transthyretin-50 familial amyloid polyneuropathy - Special reference to cardiological diagnosis and complications.  Langenbecks Arch Surg. 2000;  385 21-26
• 71 Gondo T, Ishihara T, Takahashi M, Yokota T, Yamashita Y, Nagasawa T, Kawano H, Kamei T, Okuzono Y, Uchino F, Iwata T. Immunohistochemical and ultrastructural studies of amyloid deposition in squamous cell carcinoma of uterine cervix. Amyloid and Amyloidosis. Plenum Publishing Corporation Edited by Isobe T, Araki S, Uchino F, Kito S, and Tsubura E 1988: 759-764
• 72 Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, Koike K, Aizawa M, Ikeda S. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.  Intern Med. 2003;  42 72-77
• 73 Gottenberg J E, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Combe B, Durbach A, Sibilia J, Dougados M, Mariette X. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.  Arthritis Rheum. 2003;  48 2019-2024
• 74 Gratacos J, Orellana C, Sanmarti R, Sole M, Collado A, Gomez-Casanovas E, Canete J D, Munoz-Gomez J. Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration.  J Rheumatol. 1997;  24 912-915
• 75 Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers.  Best Pract Res Clin Rheumatol. 2003;  17 929-944
• 76 Greenstein A J, Sachar D B, Panday A K, Dikman S H, Meyers S, Heimann T, Gumaste V, Werther J L, Janowitz H D. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients.  Medicine Baltimore. 1992;  71 261-270
• 77 Gupta R K, Dowle C S. Cytodiagnosis of amyloid deposition within the breast.  Cytopathology. 1996;  7 136-140
• 78 Gupta R K, Wakefield J, Halliwell T, Foo K, Lallu S, Naran S, Fauck R. Aspiration cytodiagnosis of amyloid from vitreous fluid.  Diagn Cytopathol. 2002;  26 294-296
• 79 Halliday B E, Silverman J F, Finley J L. Fine-needle aspiration cytology of amyloid associated with nonneoplastic and malignant lesions.  Diagn Cytopathol. 1998;  18 270-275
• 80 Haraoka K, Ando Y, Ando E, Sandgren O, Hirata A, Nakamura M, Terazaki H, Tajiri T, Tanoue Y, Sun X, Okabe H, Tanihara H. Amyloid deposition in ocular tissues of patients with familial amyloidotic polyneuropathy (FAP).  Amyloid. 2002;  9 183-189
• 81 Hartmann A, Holdaas H, Fauchald P, Nordal K P, Berg K J, Talseth T, Leivestad T, Brekke I B, Flatmark A. Fifteen years’ experience with renal transplantation in systemic amyloidosis.  Transpl Int. 1992;  5 15-18
• 82 Hazenberg B P, Van Rijswijk M H. Clinical and therapeutic aspects of AA amyloidosis.  Baillieres Clin Rheumatol. 1994;  8 661-690
• 83 Hazenberg B PC, Limburg P C, Bijzet J, Vanrijswijk M H. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis.  Ann Rheumatic Diseases. 1999;  58 96-102
• 84 Hazenberg B PC, Vanrijswijk M H. Where has secondary amyloid gone?.  Ann Rheumatic Diseases. 2000;  59 577-579
• 85 Helin H J, Korpela M M, Mustonen J T, Pasternack A I. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis.  Arthritis Rheum. 1995;  38 242-247
• 86 Heller H, Missmahl H P, Sohar E, Gafni J. Amyloidosis: Its differentiation into peri-reticulin and peri-collagen types.  J Pathol Bact. 1964;  88 15-34
• 87 Herlenius G, Larsson M, Ericzon B G. FAP World Transplant Register and domino/sequential register update.  Transplant Proc. 2001;  33 1367
• 88 Herlenius G, Larsson M, Ericzon B G. Results from the familial amyloidotic polyneuropathy world transplant registry.  Transplant Proc. 2001;  33 2454
• 89 Herlenius G, Wilczek H E, Larsson M, Ericzon B G. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry.  Transplantation. 2004;  77 64-71
• 90 Herrick M K, Debruyne K, Horoupian D S, Skare J, Vanefsky M A, Ong T. Massive leptomeningeal amyloidosis associated with a Val30Met transthyretin gene.  Neurology. 1996;  47 988-992
• 91 Hiroshima K, Ohwada H, Ishibashi M, Yamamoto N, Tamiya N, Yamaguchi Y. Nodular pulmonary amyloidosis associated with asbestos exposure.  Pathol Int. 1996;  46 66-70
• 92 Hirschfield G M, Hawkins P N. Amyloidosis: new strategies for treatment.  Int J Biochem Cell Biol. 2003;  35 1608-1613
• 93 Holmgren G, Ericzon B G, Groth C G, Steen L, Suhr O, Andersen O, Wallin B G, Seymour A, Richardson S, Hawkins P N, Pepys M B. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.  Lancet. 1993;  341 1113-1116
• 94 Horn U, Goebel H H, Storkel S, Bohl J, Thomas E, Schlote W, Budzilovich G. Immunohistochemistry of amyloid-related neuropathies.  Clin Neuropathol. 1991;  10 237-243
• 95 Hornsten R, Wiklund U, Olofsson B O, Jensen S M, Suhr O B. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients.  Transplantation. 2004;  78 112-116
• 96 Hund E, Singer R, Linke R P, Willig F, Grau A. Hereditary amyloidoses associated with transthyretin mutations.  Nervenarzt. 2002;  73 930-936
• 97 Ii K, Kyle R A, Dyck P J. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy.  Am J Pathol. 1992;  141 217-226
• 98 Ikeda S I, Chisuwa H, Kawasaki S, Ozawa J, Hoshii Y, Yokota T, Aoi T. Systemic reactive amyloidosis associated with Castleman’s disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.  J Clin Pathol. 1997;  50 965-967
• 99 Janssen S, Rijswijk M Hv, Meijer S, Ruinen L, Hem G. Clinical evaluation of AA and AL amyloid disease. Amyloidosis. Dordrecht-Boston-Lancester, M.Nijhoff Publ Edited by Marrink J and Van Rijswijk MH 1986: 61-72
• 100 Joss N, McLaughlin K, Simpson K, Boulton-Jones J M. Presentation, survival and prognostic markers in AA amyloidosis.  Q J Med. 2000;  93 535-542
• 101 Kagan A, Huszar M, Frumkin A, Rapoport J. Reversal of nephrotic syndrome due to AA amyloidosis in psoriatic patients on long-term colchicine treatment - Case report and review of the literature.  Nephron. 1999;  82 348-353
• 102 Kaipiainen-Seppänen O, Myllykangas-Luosujärvi R, Lampeinen E, Ikäheimo R. Intensive treatment of rheumatoid arthritis reduces need for dialysis due to secondary amyloidosis.  Scand J Rheumatol. 2000;  29 232-235
• 103 Kaplan B, Vidal R, Kumar A, Ghiso J, Gallo G. Immunochemical microanalysis of amyloid proteins in fine- needle aspirates of abdominal fat.  Am J Clin Pathol. 1999;  112 403-407
• 104 Kazatchkine M D, Husby G, Araki S, Benditt E P, Benson M D, Cohen A S, Frangione B, Glenner G G, Natvig J B, Westermark P. Nomenclature of amyloid and amyloidosis - WHO-IUIS nomenclature sub-committee.  Bull Who. 1993;  71 105-108
• 105 Kimura A, Ando E, Fukushima M, Koga T, Hirata A, Arimura K, Ando Y, Negi A, Tanihara H. Secondary glaucoma in patients with familial amyloidotic polyneuropathy.  Arch Ophthalmol. 2003;  121 351-356
• 106 Klemi P J, Sorsa S, Happonen R P. Fine-needle aspiration biopsy from subcutaneous fat. An easy way to diagnose secondary amyloidosis.  Scand J Rheumatol. 1987;  16 429-431
• 107 Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Matsumoto T, Iida M, Aoyagi K, Iwashita A, Daimaru Y, Fujishima M. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy.  Brit J Rheumatol. 1996;  35 44-49
• 108 Kobayashi S, Morita H, Asawa T, Takei Y, Hashimoto T, Ikegami T, Hashikura Y, Kawasaki S, Ikeda S. Peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation.  Amyloid. 2003;  10 17-24
• 109 Koga T, Ando E, Hirata A, Fukushima M, Kimura A, Ando Y, Negi A, Tanihara H. Vitreous opacities and outcome of vitreous surgery in patients with familial amyloidotic polyneuropathy.  Am J Ophthalmol. 2003;  135 188-193
• 110 Korbet S M, Schwartz M M, Lewis E J. The fibrillary glomerulopathies.  Am J Kidney Dis. 1994;  23 751-765
• 111 Kuroda T, Tanabe N, Sakatsume M, Nozawa S, Mitsuka T, Ishikawa H, Tohyama C T, Nakazono K, Murasawa A, Nakano M, Gejyo F. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis.  Clin Rheumatol. 2002;  21 123-128
• 112 Kyle R A, Gertz M A, Greipp P R, Witzig T E, Lust J A, Lacy M Q, Therneau T M. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.  New Engl J Med. 1997;  336 1202-1207
• 113 Kyle R A, Gertz M A, Greipp P R, Witzig T E, Lust J A, Lacy M Q, Therneau T M. Long-term survival (10 years or more) in 30 patients with primary amyloidosis.  Blood. 1999;  93 1062-1066
• 114 Kyle R A, Spencer R J, Dahlin D C. Value of rectal biopsy in the diagnosis of primary systemic amyloidosis.  Amer J Med Sci. 1966;  251 35-40
• 115 Lachmann H J, Gallimore R, Gillmore J D, Carr-Smith H D, Bradwell A R, Pepys M B, Hawkins P N. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.  Br J Haematol. 2003;  122 78-84
• 116 Laiho K, Tiitinen S, Kaarela K, Helin H, Isomaki H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland.  Clin Rheumatol. 1999;  18 122-123
• 117 Leissner J, Störkel S, Stockle M, Hohenfellner R. Primary localized amyloidosis of the bladder - a rare cause of gross hematuria.  Aktuel Urol. 1993;  24 227-231
• 118 Lew W, Seymour A E. Primary amyloid tumor of the breast. Case report and literature review.  Acta Cytol. 1985;  29 7-11
• 119 Liepnieks J J, Yazaki M, Benson M D. Continued deposition of wild-type transthyretin in cardiac amyloid after liver transplantation. Amyloid and Amyloidosis. Boca Raton, London, New York, CRC Press Edited by Grateau G, Kyle RA, and Skinner M 2004: 354-356
• 120 Linke R P. Highly sensitive diagnosis of amyloid and various amyloid syndromes using Congo red fluorescence.  Virchows Arch. 2000;  436 439-448
• 121 Linke R P, Altland K, Ernst J, Gerhard L, Michels H, Saeger W, Willig F. Praktische Hinweise zur Diagnose und Therapie generalisierter Amyloidosen.  Dtsch Ärztebl. 1998;  95 B2048-B2055
• 122 Löfberg H, Grubb A, Thysell H, Nilsson E, Kjellander B, Moller C, Gruic V, Ljungquist A, Sternby N H. The prevalence of renal amyloidosis of the AA-type in a series of 1,158 consecutive autopsies.  Acta Pathol Microbiol Immunol Scand A. 1987;  95 297-302
• 123 Maezawa A, Hiromura K, Mitsuhashi H, Tsukada Y, Kanai H, Yano S, Naruse T. Combined treatment with cyclophosphamide and prednisolone can induce remission of nephrotic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis.  Clin Nephrol. 1994;  42 30-32
• 124 Mascalchi M, Salvi F P, Pirini M G, Derrico A, Ferlini A, Lolli F, Plasmati R, Tessa C, Villari N, Tassinari C A. Transthyretin amyloidosis and superficial siderosis of the CNS.  Neurology. 1999;  53 1498-1503
• 125 Masouye I. Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases.  Am J Dermatopathol. 1997;  19 41-45
• 126 Matsuda M, Morita H, Ikeda S. Long-term follow-up of systemic reactive AA amyloidosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose corticosteroid.  Intern Med. 2002;  41 403-407
• 127 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis.  N Engl J Med. 2003;  349 583-596
• 128 Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies.  J Intern Med. 2004;  255 159-178
• 129 Metternich F U, Brusis T. Surgical ENT therapy of oropharyngeal amyloidosis.  Laryngorhinootologie. 1998;  77 231-234
• 130 Missmahl H P. Amyloidosen bei chronisch rheumatischen Erkrankungen.  Verh Dtsch Ges Inn Med. 1968;  74 1102-1116
• 131 Missmahl H P, Böhmer R. Amyloidniere. Klinische Nephrologie. Stuttgart, G.Thieme Edited by Losse H and Renner E 1982: 266-272
• 132 Mohty M, Albat B, Fegueux N, Rossi J F. Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis.  Leuk Lymphoma. 2001;  41 221-223
• 133 Moroni G, Banfi G, Montoli A, Bucci A, Bertani T, Ravelli M, Pozzi C, Leonelli M, Lupo A, Volpi A. Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy.  Clin Nephrol. 1992;  38 81-85
• 134 Mpofu S, Teh L S, Smith P J, Moots R J, Hawkins P N. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy.  Rheumatology (Oxford). 2003;  42 362-366
• 135 Mumford A D, ODonnell J, Gillmore J D, Manning R A, Hawkins P N, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.  Brit J Haematol. 2000;  110 454-460
• 136 Munar-Ques M, Salva-Ladaria L, Mulet-Perera P, Sole M, Lopez-Andreu F R, Saraiva M J. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin.  Amyloid. 2000;  7 266-269
• 137 Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland.  Rheumatology. 1999;  38 499-503
• 138 Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T, Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M, Yamamura K. Targeted conversion of the transthyretin gene in vitro and in vivo.  Gene Ther. 2004;  11 838-846
• 139 Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis.  Clin Rheumatol. 2003;  22 371-375
• 140 Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, Kuroda T, Sato T, Maruyama Y, Arakawa M. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis.  Clin Nephrol. 1998;  50 154-160
• 141 Obici L, Manno C, Muda A O, Picco P, D’Osualdo A, Palladini G, Avanzini M A, Torres D, Marciano S, Merlini G. First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome.  Arthritis Rheum. 2004;  50 2966-2969
• 142 Odabas A R, Cetinkaya R, Selcuk Y, Bilen H. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis.  Ups J Med Sci. 2001;  106 183-188
• 143 Olofsson B O, Backman C, Karp K, Suhr O B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type.  Transplantation. 2002;  73 745-751
• 144 Olsen K E, Sletten K, Westermark P. Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: Kappa IV immunoglobulin light chain.  Biochem Biophys Res Commun. 1998;  245 713-716
• 145 Olsen K E, Sletten K, Westermark P. The use of subcutaneous fat tissue for amyloid typing by enzyme- linked immunosorbent assay.  Am J Clin Pathol. 1999;  111 355-362
• 146 Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A. Anti-TNF treatment in secondary amyloidosis.  Rheumatology (Oxford). 2003;  42 1425-1426
• 147 Palha J A, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti V, Merlini G, Saraiva M J. 4’-Iodo-4’-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid.  Am J Pathol. 2000;  156 1919-1925
• 148 Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G, Merlini G. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.  Blood. 2004;  103 2936-2938
• 149 Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).  Blood. 2005;  105 2949-2951
• 150 Pambuccian S E, Horyd I D, Cawte T, Huvos A G. Amyloidoma of bone, a plasma cell/plasmacytoid neoplasm: Report of three cases and review of the literature.  Am J Surg Pathol. 1997;  21 179-186
• 151 Pasternack A, Ahonen J, Kuhlback B. Renal transplantation in 45 patients with amyloidosis.  Transplantation. 1986;  42 598-601
• 152 Patriarca F, Geromin A, Fanin R, Damiani D, Sperotto A, Baccarani M. Improvement of amyloid-related symptoms after autologous stem cell transplantation in a patient with hepatomegaly, macroglossia and purpura.  Bone Marrow Transplant. 1999;  24 433-435
• 153 Pepys M B, Hawkins P N, Booth D R, Vigushin D M, Tennent G A, Soutar A K, Totty N, Nguyen O, Blake C CF, Terry C J, Feest T G, Zalin A M, Hsuan J J. Human lysozyme gene mutations cause hereditary systemic amyloidosis.  Nature. 1993;  362 553-557
• 154 Perico N, Remuzzi G. Angiotensin II receptor antagonists and treatment of hypertension and renal disease.  Curr Opin Nephrol Hypertens. 1998;  7 571-578
• 155 Perz J B, Schonland S O, Hundemer M, Kristen A V, Dengler T J, Zeier M, Linke R P, Ho A D, Goldschmidt H. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.  Br J Haematol. 2004;  127 543-551
• 156 Petersen R B, Goren H, Cohen M, Richardson S L, Tresser N, Lynn A, Gali M, Estes M, Gambetti P. Transthyretin amyloidosis: A new mutation associated with dementia.  Ann Neurol. 1997;  41 307-313
• 157 Piazza C, Cavaliere S, Foccoli P, Toninelli C, Bolzoni A, Peretti G. Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients.  Eur Arch Otorhinolaryngol. 2003;  260 349-354
• 158 Pizov G, Soffer D. Amyloid tumor (amyloidoma) of a peripheral nerve.  Arch Pathol Lab Med. 1986;  110 969-970
• 159 Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, Misrahi M, Said G, Bonaiti-Pellie C. Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families.  J Med Genet. 2003;  40 e120
• 160 Plante-Bordeneuve V, Lalu T, Misrahi M, Reilly M M, Adams D, Lacroix C, Said G. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy.  Neurology. 1998;  51 708-714
• 161 Prayson R A. Amyloid myopathy: Clinicopathologic study of 16 cases.  Hum Pathol. 1998;  29 463-468
• 162 Pröpsting M J, Blaschke M, Haas R E, Genschel J, Hedrich H J, Manns M P, Schmidt H H. Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation.  Biochem Biophys Res Commun. 1999;  260 313-317
• 163 Pröpsting M J, Kubicka S, Genschel J, Manns M P, Lochs H, Schmidt H H. Inhibition of transthyretin-met30 expression using Inosine(15.1)-Hammerhead ribozymes in cell culture.  Biochem Biophys Res Commun. 2000;  279 970-973
• 164 Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid.  J Histochem Cytochem. 1962;  10 355-364
• 165 Queffeulou G, Berentbaum F, Michel C, Mougenot B, Mignon F. AA amyloidosis in systemic lupus erythematosus: an unusual complication.  Nephrol Dial Transplant. 1998;  13 1846-1848
• 166 Rajani B, Rajani V, Prayson R A. Peripheral nerve amyloidosis in sural nerve biopsies - A clinicopathologic analysis of 13 cases.  Arch Pathol Lab Med. 2000;  124 114-118
• 167 Reilly M M, Staunton H, Harding A E. Familial amyloid polyneuropathy (TTR ala 60) in north west ireland: a clinical, genetic, and epidemiological study.  J Neurol Neurosurg Psychiatry. 1995;  59 45-49
• 168 Röcken C, Saeger W, Linke R P. Gastrointestinal amyloid deposits in old age. Report on 110 consecutive autopsical patients and 98 retrospective bioptic specimens.  Path Res Pract. 1994;  190 641-649
• 169 Röcken C, Schwotzer E, Linke R P, Saeger W. The classification of amyloid deposits in clinicopathological practice.  Histopathology. 1996;  29 325-335
• 170 Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.  Lancet. 1998;  352 1252-1256
• 171 Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).  Lancet. 1997;  349 1857-1863
• 172 Saeger W, Röcken C, Linke R P. Amyloiddiagnostik in der klinischen Pathologie.  HÄB. 1993;  1 9-14
• 173 Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M, Terazaki H, Obayashi K, Takeya M. Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage.  PATHOL INT. 2001;  51 476-480
• 174 Sanchorawala V, Wright D G, Seldin D C, Falk R H, Finn K T, Dember L M, Berk J L, Quillen K, Anderson J J, Comenzo R L, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.  Bone Marrow Transplant. 2004;  33 381-388
• 175 Saraiva M J. Transthyretin amyloidosis: a tale of weak interactions.  FEBS Lett. 2001;  498 201-203
• 176 Schena F P, Pannarale G, Carbonara M C. Clinical and therapeutic aspects of renal amyloidosis.  Nephrol Dial Transplant. 1996;  (Suppl 9) 11 63-68
• 177 Schmidt H H, Nashan B, Pröpsting M J, Nakazato M, Flemming P, Kubicka S, Boker K, Pichlmayr R, Manns M P. Familial Amyloidotic Polyneuropathy: domino liver transplantation.  J Hepatol. 1999;  30 293-298
• 178 Schmidt H HJ, Pröpsting M J, Manns M P. Familial amyloidosis.  Internist. 1999;  40 493-501
• 179 Schneider F. AA-amyloidosis in inflammatory rheumatic diseases. A report of clinical experiences.  Z Rheumatol. 1992;  51 177-182
• 180 Schnitzer T J, Ansell B M. Amyloidosis in juvenile chronic polyarthritis.  Arthritis Rheum. 1977;  20 245-252
• 181 Serratrice J, Granel B, Disdier P, Weiller P J, Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still’s disease.  Am J Med. 2003;  115 589-590
• 182 Sezer O, Eucker J, Jakob C, Possinger K. Diagnosis and treatment of AL amyloidosis.  Clin Nephrol. 2000;  53 417-423
• 183 Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis.  Ann Hematol. 2000;  79 1-6
• 184 Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H, Possinger K. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.  Bone Marrow Transplant. 1999;  23 967-969
• 185 Shapiro D L, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report.  Arthritis Rheum. 1995;  38 1851-1854
• 186 Shaz B H, Lewis W D, Skinner M, Khettry U. Livers from patients with apolipoprotein A-I amyloidosis are not suitable as „domino” donors.  Mod Pathol. 2001;  14 577-580
• 187 Shaz H B, Gordon F, Lewis W D, Jenkins R L, Skinner M, Khettry U. Orthotopic liver transplantation for familial amyloidotic polyneuropathy: A pathological study.  Hum Pathol. 2000;  31 40-44
• 188 Simmons Z, Blaivas M, Aguilera A J, Feldman E L, Bromberg M B, Towfighi J. Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis.  J Neurol Sci. 1993;  120 60-63
• 189 Skinner M, Sanchorawala V, Seldin D C, Dember L M, Falk R H, Berk J L, Anderson J J, O’Hara C, Finn K T, Libbey C A, Wiesman J, Quillen K, Swan N, Wright D G. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.  Ann Intern Med. 2004;  140 85-93
• 190 Smith G R, Tymms K E, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis.  Intern Med J. 2004;  34 570-572
• 191 Soto C. Protein misfolding and disease, protein refolding and therapy.  FEBS Lett. 2001;  498 204-207
• 192 Sousa M M, Ferrao J, Fernandes R, Guimaraes A, Geraldes J B, Perdigoto R, Tome L, Mota O, Negrao L, Furtado A L, Saraiva M J. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers.  Lab Invest. 2004;  84 865-873
• 193 Spuler S. Amyloid-Myopathie. Muskelkrankheiten. Schattauer Verlag Edited by Spuler S and Moers A 2004: 253-256
• 194 Spuler S, Emslie-Smith A, Engel A G. Amyloid myopathy: an underdiagnosed entity.  Ann Neurol. 1998;  43 719-728
• 195 Stangou A J, Hawkins P N, Heaton N D, Rela M, Monaghan M, Nihoyannopoulos P, Ogrady J, Pepys M B, Williams R. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy - Implications for amyloid fibrillogenesis.  Transplantation. 1998;  66 229-233
• 196 Stangou A J, Heaton N D, Hawkins P N. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation.  New Engl J Med. 2005;  352 2356
• 197 Stangou A J, Heaton N D, Rela M, O’Grady J, Mathias C J, Goodman H JB, Lachmann H, Bybee A, Rowzcenio D, Joshi J, Williams R S, Pepys M B, Hawkins P N. Liver transplantation in ATTR Met30 andother variants: time to shift the paradigm? Amyloid and Amyloidosis. Boca Reton, London, New York, CRC Press Edited by Grateau G, Kyle RA, and Skinner M 2004: 306-308
• 198 Stangou A J, Heaton N D, Rela M, Pepys M B, Hawkins P N, Williams R. Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy.  Transplantation. 1998;  65 1496-1498
• 199 Suhr O B, Ando Y, Holmgren G, Wikstrom L, Friman S, Herlenius G, Ericzon B G. Liver transplantation in familial amyloidotic polyneuropathy (FAP): A comparative study of transplanted and non-transplanted patient’s survival.  Transpl Int. 1998;  (Suppl 1) 11 S160-S163
• 200 Suhr O B, Svendsen I H, Andersson R, Danielsson A, Holmgren G, Ranlov P J. Hereditary transthyretin amyloidosis from a Scandinavian perspective.  J Intern Med. 2003;  254 225-235
• 201 Syversen P V, Juul J, Marhaug G, Husby G, Sletten K. The primary structure of serum amyloid-a protein in the sheep - comparison with serum amyloid-a in other species.  Scand J Immunol. 1994;  39 88-94
• 202 Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, Yamasaki S, Ida H, Kawakami A, Origuchi T, Eguchi K. Clinical outcome and survival of secondary (AA) amyloidosis.  Clin Exp Rheumatol. 2003;  21 343-346
• 203 Tashima K, Suhr O B, Ando Y, Holmgren G, Yamashita T, Obayashi K, Terazaki H, Uchino M. Gastrointestinal dysfunction in familial amyloidotic polyneuropathy (ATTR Val30Met) - comparison of Swedish and Japanese patients.  Amyloid. 1999;  6 124-129
• 204 Tietz A. Familiäre Amyloidose im Mannheimer Norden. Universität Heidelberg-Mannheim 2000
• 205 Tishler M, Pras M, Yaron M. Abdominal fat tissue aspirate in amyloidosis of familial Mediterranean fever.  Clin Exp Rheumatol. 1988;  6 395-397
• 206 Tomero E, Carmona L, Gonzalez-Alvaro I, Ortiz A M, Ruiz-Zorilla A, Laffon A, Garcia-Vicuna R. Infliximab in secondary amyloidosis complicating inflammatory arthropathies.  Arthritis and Rheumatism. 2002;  46 72
• 207 Toth T, Toth-Jakatics R, Jimi S, Takebayashi S. Increased density of interstitial mast cells in amyloid. A renal amyloidosis.  Modern Pathol. 2000;  13 1020-1028
• 208 Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, Ataman R, Akpolat T, Ok E, Sen S, Dusunsel R, Evrenkaya R, Akoglu E. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey.  Nephrol Dial Transplant. 2002;  17 2003-2005
• 209 Uemichi T, Liepnieks J J, Gertz M A, Benson M D. Fibrinogen A alpha chain Leu 554: an African-American kindred with late onset renal amyloidosis.  Amyloid. 1998;  5 188-192
• 210 Umezawa M, Tatematsu K, Korenaga T, Fu X, Matushita T, Okuyama H, Hosokawa M, Takeda T, Higuchi K. Dietary fat modulation of apoA-II metabolism and prevention of senile amyloidosis in the senescence - accelerated mouse.  J Lipid Res. 2003;  44 762-769
• 211 Utz J P, Swensen S J, Gertz M A. Pulmonary amyloidosis - The Mayo Clinic experience from 1980 to 1993.  Ann Int Med. 1996;  124 407-413
• 212 Van Allen M W, Frohlich J A, Davis J R. Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer.  Neurology. 1969;  19 10-25
• 213 van Gameren I I, Hazenberg B P, Jager P L, Smit J W, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.  Amyloid. 2002;  9 165-174
• 214 Varga J, Idelson B A, Felson D, Skinner M, Cohen A S. Lack of amyloid in abdominal fat aspirates from patients undergoing long-term hemodialysis.  Arch Intern Med. 1987;  147 1455-1457
• 215 Vavrina J, Muller W, Gebbers J O. Recurrent amyloid tumor of the parotid gland.  Eur Arch Otorhinolaryngol. 1995;  252 53-56
• 216 Verschueren P, Lensen F, Lerut E, Claes K, De Vos R, Van Damme B, Westhovens R. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.  Ann Rheumatic Diseases. 2003;  62 368-369
• 217 Wester A L, Vatn M H, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998.  Inflamm Bowel Dis. 2001;  7 295-300
• 218 Westermark P, Benson L, Olofsson B O. Fine needle aspiration biopsy of abdominal subcutaneous fat tissue for the diagnosis and typing of amyloidosis. Amyloidosis. New York, London, Plenum Publishimg Corporation Edited by Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, and Zucker-Franklin D 1986: 613-615
• 219 Westermark P, Stenkvist B. A new method for the diagnosis of systemic amyloidosis.  Arch Int Med. 1973;  132 522-523
• 220 Willig F. AA amyloidosis in Crohn’s disease, consequences for appraisal of incapacitation.  Pathology Research and Practice. 1999;  195 372
• 221 Woollons A, Black M M. Nodular localized primary cutaneous amyloidosis: a long-term follow-up study.  Br J Dermatol. 2001;  145 105-109
• 222 Yamada M, Hatakeyama S, Tsukagoshi H. Gastrointestinal amyloid deposition in AL (primary or myeloma-associated) and AA (secondary) amyloidosis: diagnostic value of gastric biopsy.  Hum Pathol. 1985;  16 1206-1211
• 223 Yamada M, Hatakeyama S, Yamamoto E, Kimura Y, Tsukagoshi H, Yokota T, Uchino F. Localized amyloidosis of the uterine cervix.  Virchows Archiv [A]. 1988;  413 265-268
• 224 Yazaki M, Liepnieks J J, Yamashita T, Guenther B, Skinner M, Benson M D. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene.  Kidney Int. 2001;  60 1658-1665
• 225 Ylinen K, G ronhagen-Riska C, Honkanen E, Ekstrand A, Metsarinne K, Kuhlback B. Outcome of patients with secondary amyloidosis in dialysis treatment.  Nephrol Dial Transplant. 1992;  7 908-912
• 226 Zhu L C, Sidhu G S, Yee H T, Cassai N D, Goldfarb D S, Wieczorek R L. AA-type amyloidosis associated with non-Hodgkin’s lymphoma: a case report.  Hum Pathol. 2004;  35 1041-1044